Cancer vaccine from Moderna, Merck shows promise in late-stage trial; both stocks soar
Reported by CNBC · cnbc.com · August 19, 2026
The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.
What the tape says
What to watch: Potential opportunity in Markets — evaluate fundamentals before acting.
Market reaction today: $MRK -1.24%, $MRNA -4.30%
Tone and severity are deterministic keyword classification — not a prediction, a member vote, or a recommendation. Figures are extracted from the headline as published. Wook does not republish CNBC's reporting.
Your read
Discussion
No one has weighed in yet. Start the discussion on this story.
Headline and link are attributed to CNBC. Wook of Wall Street is an independent research tool and is not affiliated with CNBC. Nothing here is financial advice or a recommendation — research and educational content only.